A recent study examining the closure of a supervised consumption site in Red Deer, Alberta, has ignited a contentious debate over the effectiveness of such facilities. Published in the journal Addiction, the research found that fatalities and emergency department visits did not increase among former clients after the site shut down.
Study Findings and Reactions
The study, released in early March, was conducted by the Canadian Centre of Recovery Excellence (CoRE), a recovery-oriented research entity funded by the Alberta government. It utilized anonymized health data to track outcomes for clients of the closed injection site. The results contradicted claims that such sites are essential for preventing overdoses and reducing emergency room visits.
Alberta Premier Danielle Smith shared a column about the study on social media, drawing attention to its conclusions. However, critics quickly emerged. Guy Felicella, a prominent pro-injection site advocate, labeled the study as “methodologically flawed” and suggested that “something stinks.” More detailed criticism appeared in an op-ed in the Edmonton Journal and a subsequent letter to the editor in Addiction.
Academic Concerns
Dan Werb, a scientist with MAP Centre for Urban Health Solutions in Toronto and a supporter of injection sites, expressed concerns about the study. He pointed to potential conflicts of interest, noting that CoRE receives public funding from the Alberta government. The study includes a disclaimer stating that the funder had no role in the research design or analysis. Werb also objected to the use of personal health numbers to track clients, describing it as “surveillance” at what are meant to be low-barrier services.
Despite these criticisms, the study's lead author, Dr. Nathaniel Day, emphasized that the data was anonymized to protect privacy. A 2024 University of Alberta report found that only 1.2% of drug users surveyed considered providing personal information a barrier to using injection sites, suggesting that such requirements do not significantly hinder access.
Implications for Policy
The debate highlights the ongoing tension between harm reduction advocates and those who question the efficacy of supervised consumption sites. Proponents argue that these facilities save lives by preventing overdoses and connecting users to treatment, while opponents point to studies like this one to challenge those claims. The Red Deer study represents a significant contribution to the evidence base, as it is one of the first to assess the effects of injection site closure using individual-level, linkable administrative health data.
As the discussion continues, policymakers must weigh the available research against the passionate arguments from both sides. The findings from Red Deer suggest that the closure of an injection site does not necessarily lead to increased harm, but further studies are needed to confirm these results in other contexts.
